7-(benzyloxy)-4-(3-fluoro-4-nitrophenoxy)-6-methoxyquinoline | 286371-58-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 7-(benzyloxy)-4-(3-fluoro-4-nitrophenoxy)-6-methoxyquinoline
• 英文别名: 4-(3-fluoro-4-nitrophenoxy)-6-methoxy-7-phenylmethoxyquinoline
• CAS: 286371-58-2
• 化学式: C₂₃H₁₇FN₂O₅
• 分子量: 420.397
• InChiKey: VBWIXDSYELQNES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  86.4
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  7-(benzyloxy)-4-(3-fluoro-4-nitrophenoxy)-6-methoxyquinoline 在 氯化铵 作用下， 以 乙醇 、 水 为溶剂， 反应 18.0h， 以94%的产率得到4-{[7-(苄氧基)-6-甲氧基-4-喹啉基]氧基}-2-氟苯胺
  参考文献：
  名称：

  QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME

  摘要：

  公开号：

  EP1411046B1
• 作为产物：
  描述：

  7-苄氧基-4-氯-6-甲氧基喹啉 、 3-氟-4-硝基苯酚 以 氯苯 为溶剂， 反应 16.0h， 生成 7-(benzyloxy)-4-(3-fluoro-4-nitrophenoxy)-6-methoxyquinoline
  参考文献：
  名称：

  4-((4-(4-(3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)ureido)-2-fluorophenoxy)-6-methoxyquinolin-7-yl)oxy 的发现)-N,N-diethylpiperidine-1-carboxamide 作为激酶抑制剂治疗结直肠癌

  摘要：

  在这项研究中，基于我们之前的研究，设计并合成了一系列带有噻唑烷酮的新型 4,6,7-三取代喹啉类似物。其中，效力最强的化合物15i，4-((4-(4-(3-(2-(2,6-二氟苯基)-4-oxothiazolidin-3-yl)ureido)-2-fluorophenoxy)-6-甲氧基喹啉-7-基)氧基) -N,N-二乙基哌啶-1-甲酰胺被鉴定为多激酶抑制剂。MTT 测定结果显示化合物15i对 HT-29 细胞的体外抗肿瘤活性，IC 50值 0.19 μM，比 Regorafenib 强 14.5 倍。在细胞环境中，通过 IncuCyte 活细胞成像分析证实了 HT-29 细胞以剂量和时间依赖性方式显着的抗增殖、细胞毒性和凋亡诱导。此外，化合物15i通过将细胞周期阻滞到 G2/M 期来强烈诱导细胞凋亡。在10.0 μg/mL或更低浓度下未观察到对人正常结直肠粘膜上皮细胞FHC的抗增殖和细

  DOI：

  10.1016/j.bioorg.2020.104511

文献信息

• Quinoline derivatives and quinazoline derivatives
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：US20040209905A1

  公开（公告）日：2004-10-21

  An object of the present invention is to provide compounds which have antitumor activity and do not change cytomorphosis. Disclosed are compounds represented by formula (I) and a pharmaceutically acceptable salts and solvates thereof and pharmaceutical compositions comprising said compounds: 1 wherein X and Z each independently represent CH or N; R 1 to R 3 represent H, substituted alkoxy, unsubstituted alkoxy or the like; R 4 represents H; R 5 to R 8 represent H, halogen, alkyl, alkoxy, alkylthio, nitro, or amino, provided that R 5 to R 8 do not simultaneously represent H; R 9 and R 10 represent H, alkyl, or alkylcarbonyl; and R 11 represents alkyl, alkenyl, alkynyl, or aralkyl.

  本发明的目的是提供具有抗肿瘤活性且不改变细胞形态的化合物。本发明揭示了由式（I）表示的化合物，以及其药学上可接受的盐和溶剂和包含所述化合物的制药组合物：1其中X和Z各自独立地表示CH或N; R1至R3表示H、取代烷氧基、未取代烷氧基或类似物; R4表示H; R5至R8表示H、卤素、烷基、烷氧基、烷基硫基、硝基或氨基，但要求R5至R8不同时表示H; R9和R10表示H、烷基或烷基羰基; 而R11表示烷基、烯基、炔基或芳基烷基。
• Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same
  申请人：——

  公开号：US20040242603A1

  公开（公告）日：2004-12-02

  An objective of the present invention is to provide compounds having potent antitumor activity. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: 1 wherein X=CH or N; Z=O or S; L=O or S; M=CR 10 R 11 , wherein R 10 and R 11 =H, alkyl, or alkoxy, NR 12 wherein R 12 =H or alkyl; R 1 , R 2 , and R 3 =H or optionally substituted alkoxy; R 4 =H; R 5-8 =H, halogen, alkoxy or the like; and R 9 =alkyl optionally substituted by —R 14 , -T-R 15 , or —NR 16 R 17 wherein T=O, S, or NH; R 14 =an optionally substituted carbocyclic or heterocyclic ring; and R 15-17 =alkyl or an optionally substituted carbocyclic or heterocyclic ring, or —NR 18 R 19 wherein R 18 and R 19 =H, optionally substituted alkyl, or an optionally substituted carbocylic or heterocyclic ring, or optionally substituted carbocyclic or heterocyclic ring.

  本发明的目标是提供具有强效抗肿瘤活性的化合物。本发明的化合物由以下式子（I）或其药学上可接受的盐或溶剂表示：1其中X = CH或N；Z = O或S；L = O或S；M = CR10R11，其中R10和R11 = H，烷基或烷氧基，NR12，其中R12 = H或烷基；R1、R2和R3 = H或可选取代烷氧基；R4 = H；R5-8 = H、卤素、烷氧基或类似物；以及R9 = 烷基，可选取代-R14、-T-R15或-NR16R17，其中T = O、S或NH；R14 = 可选取代的碳环或杂环；R15-17 = 烷基或可选取代的碳环或杂环，或-NR18R19，其中R18和R19 = H、可选取代的烷基或可选取代的碳环或杂环，或可选取代的碳环或杂环。
• Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors
  申请人：Miwa Atsushi

  公开号：US20050049264A1

  公开（公告）日：2005-03-03

  An objective of the present invention is to provide novel compounds which have inhibitory activity against autophosphorylation of an FGF receptor family and, when orally or intraveneously administered, can suppress the growth of cancer cells. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; Q represents NR 10 , CR 11 R 2 , carbonyl, O, S(═O)m, wherein m is 0 to 2, or urea; R 1 to R 3 each independently represent H, OH, halogen, nitro, amino, alkyl, alkoxy or the like in which the alkyl and alkoxy groups are optionally substituted; R 4 represents H; R 5 to R 8 each independently represent H, halogen, alkyl, or alkoxy; and R 9 represents an optionally substituted carbocyclic or heterocyclic group.

  本发明的目标是提供新型化合物，其具有对FGF受体家族自磷酸化的抑制活性，并在口服或静脉注射时能够抑制癌细胞的生长。本发明的化合物由公式（I）或其药学上可接受的盐或溶剂表示：其中X代表CH或N; Z代表O或S; Q代表NR10，CR11R2，羰基，O，S（═O）m，其中m为0到2，或脲基; R1至R3各自独立地表示H、OH、卤素、硝基、氨基、烷基、烷氧基或其类似物，其中烷基和烷氧基基团可选择性地被取代; R4表示H; R5至R8各自独立地表示H、卤素、烷基或烷氧基; R9表示一个可选择性取代的碳环或杂环基团。
• Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same
  申请人：Miwa Atsushi

  公开号：US20080207617A1

  公开（公告）日：2008-08-28

  An objective of the present invention is to provide compounds and pharmaceuticals useful for the treatment of disease where the inhibition of autophosphorylation of FMS-like tyrosine kinase 3(Flt3) is therapeutically effective. The present invention relates to a pharmaceutical composition for use in the treatment or prevention of diseases where the inhibition of autophosphorylation of Flt3 therapeutically or prophylactically effective, which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; R 1 , R 2 , and R 3 represent H, OH, or optionally substituted alkoxy; R 4 represents H; R 5 , R 6 , R 7 , and R 8 represent H, Hal, alkyl or the like; and R 9 represents, e.g., alkyl substituted by t-butyl or the like.

  本发明的目标是提供化合物和药物，用于治疗抑制FMS样酪氨酸激酶3（Flt3）自磷酸化在治疗上具有疗效的疾病。本发明涉及一种药物组合物，用于治疗或预防抑制Flt3自磷酸化在治疗或预防上具有疗效的疾病，所述药物组合物包括以下公式（I）所表示的化合物或其药学上可接受的盐或溶剂：其中X代表CH或N；Z代表O或S；R1、R2和R3代表H、OH或可选取代的烷氧基；R4代表H；R5、R6、R7和R8代表H、卤素、烷基或类似物；R9代表例如被t-丁基或类似物取代的烷基。
• Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：EP1384712A1

  公开（公告）日：2004-01-28

  An object of the present invention is to provide compounds which have antitumor activity and do not change cytomorphosis. Disclosed are compounds represented by formula (I) and a pharmaceutically acceptable salts and solvates thereof and pharmaceutical compositions comprising said compounds: wherein X and Z each independently represent CH or N; R1 to R3 represent H, substituted alkoxy, unsubstituted alkoxy or the like; R4 represents H; R5 to R8 represent H, halogen, alkyl, alkoxy, alkylthio, nitro, or amino, provided that R5 to R8 do not simultaneously represent H; R9 and R10 represent H, alkyl, or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl, or aralkyl.

  本发明的目的是提供具有抗肿瘤活性且不改变细胞形态的化合物。本发明公开了式(I)代表的化合物及其药学上可接受的盐和溶液以及包含所述化合物的药物组合物： 其中X和Z各自独立地代表CH或N；R1至R3代表H、取代的烷氧基、未取代的烷氧基或类似物；R4代表H；R5至R8代表H、卤素、烷基、烷氧基、烷硫基、硝基或氨基，但R5至R8不同时代表H；R9和R10代表H、烷基或烷基羰基；R11代表烷基、烯基、炔基或芳烷基。